Wolf-Henning Boehncke, A. Reich, Sonja Ständer, Julio Hernandez, C. Mert, S. Grond, M. J. Rueda, C. Schuster, Gil Yosipovitch
Itch is known to have a particularly high impact on psoriasis (PsO) and atopic dermatitis (AD) patients' quality of life. Although AD therapies have exhibited a high efficacy when it comes to itch control, itch control with PsO therapies is not as well documented.The aim of this post‐hoc analysis is to better understand the impact of itch on the patients' quality of life in PsO as well as AD by providing a pairwise correlation between itch improvement and patients' quality of life and determine the predictive factors in patients achieving Dermatology Life Quality Index score of 0 or 1 [DLQI (0/1)].Three phase III clinical studies, one in PsO and two in AD, were assessed. Pairwise correlations between objective improvement of visible signs of disease, quality of life, and itch intensity were investigated at 16 weeks of treatment. Predictive analyses methods were applied on the data to assess the impact of clinical and itch improvement on the DLQI improvement.This study shows that change in itch from baseline in AD and PsO patients correlate to change in DLQI from baseline. Change in itch from baseline was found to be the most important factor in predicting DLQI (0/1).These results highlight the necessity to study itch in both PsO and AD clinical trials, and it is recommended that itch may be considered a coprimary or at minimum a secondary efficacy end‐point in all such clinical studies.
众所周知,瘙痒对银屑病(PsO)和特应性皮炎(AD)患者的生活质量影响特别大。这项事后分析的目的是通过提供瘙痒改善与患者生活质量之间的成对相关性,更好地了解瘙痒对银屑病和特应性皮炎患者生活质量的影响,并确定皮肤病生活质量指数(DLQI)达到 0 分或 1 分的患者的预测因素。评估了三项 III 期临床研究,其中一项针对 PsO,另两项针对 AD。研究调查了治疗 16 周时疾病可见体征的客观改善、生活质量和瘙痒强度之间的配对相关性。该研究表明,AD 和 PsO 患者瘙痒程度从基线开始的变化与 DLQI 从基线开始的变化相关。这些结果凸显了在 PsO 和 AD 临床试验中研究瘙痒的必要性,建议在所有此类临床研究中将瘙痒视为主要或至少是次要疗效终点。
{"title":"Itch improvement has a major and comparable effect on the Dermatology Life Quality Index in psoriasis and atopic dermatitis patients","authors":"Wolf-Henning Boehncke, A. Reich, Sonja Ständer, Julio Hernandez, C. Mert, S. Grond, M. J. Rueda, C. Schuster, Gil Yosipovitch","doi":"10.1002/jvc2.509","DOIUrl":"https://doi.org/10.1002/jvc2.509","url":null,"abstract":"Itch is known to have a particularly high impact on psoriasis (PsO) and atopic dermatitis (AD) patients' quality of life. Although AD therapies have exhibited a high efficacy when it comes to itch control, itch control with PsO therapies is not as well documented.The aim of this post‐hoc analysis is to better understand the impact of itch on the patients' quality of life in PsO as well as AD by providing a pairwise correlation between itch improvement and patients' quality of life and determine the predictive factors in patients achieving Dermatology Life Quality Index score of 0 or 1 [DLQI (0/1)].Three phase III clinical studies, one in PsO and two in AD, were assessed. Pairwise correlations between objective improvement of visible signs of disease, quality of life, and itch intensity were investigated at 16 weeks of treatment. Predictive analyses methods were applied on the data to assess the impact of clinical and itch improvement on the DLQI improvement.This study shows that change in itch from baseline in AD and PsO patients correlate to change in DLQI from baseline. Change in itch from baseline was found to be the most important factor in predicting DLQI (0/1).These results highlight the necessity to study itch in both PsO and AD clinical trials, and it is recommended that itch may be considered a coprimary or at minimum a secondary efficacy end‐point in all such clinical studies.","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141927095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fiona André, Martha Bujak, Nina Frischhut, Andreas Kronbichler, N. Sepp, G. Ratzinger, Barbara Böckle
Sjögren syndrome (SS) is a systemic autoimmune disease characterised by oral and ocular mucosal dryness.Our study focused on skin manifestations of SS. The differences between primary SS (pSS) and secondary SS (sSS) were investigated. Furthermore, we elucidated factors predicting internal organ involvement.This was a single centre retrospective cohort study. We analysed clinical and laboratory data from 185 Ro‐SSA positive SS patients between January 2000 and December 2016.Skin manifestations were present in 74.9% (n = 137) of SS patients. Dermatitis and Lupus erythematosus (LE)‐specific skin manifestations were present in 34.1% (n = 63) and 21.6% (n = 40) of SS patients respectively. 65.9% (n = 122) of SS patients had internal organ involvement, with 53% (n = 98) presenting neuropsychiatric manifestations. Several risk factors for internal organ involvement were identified: presence of myalgia/arthralgia (odds ratio [OR] = 3.05, confidence interval [CI] 1.29−7.22), fatigue (OR = 2.53, CI 1.11−5.73) and age older than 50 years (OR = 2.23, CI 1.01−4.93).Internal organ involvement is frequent in SS, however there is no significant difference between pSS and sSS concerning its occurrence.
{"title":"Sjögren syndrome from a dermatological perspective: A retrospective study of 185 SSA‐Ro positive patients","authors":"Fiona André, Martha Bujak, Nina Frischhut, Andreas Kronbichler, N. Sepp, G. Ratzinger, Barbara Böckle","doi":"10.1002/jvc2.498","DOIUrl":"https://doi.org/10.1002/jvc2.498","url":null,"abstract":"Sjögren syndrome (SS) is a systemic autoimmune disease characterised by oral and ocular mucosal dryness.Our study focused on skin manifestations of SS. The differences between primary SS (pSS) and secondary SS (sSS) were investigated. Furthermore, we elucidated factors predicting internal organ involvement.This was a single centre retrospective cohort study. We analysed clinical and laboratory data from 185 Ro‐SSA positive SS patients between January 2000 and December 2016.Skin manifestations were present in 74.9% (n = 137) of SS patients. Dermatitis and Lupus erythematosus (LE)‐specific skin manifestations were present in 34.1% (n = 63) and 21.6% (n = 40) of SS patients respectively. 65.9% (n = 122) of SS patients had internal organ involvement, with 53% (n = 98) presenting neuropsychiatric manifestations. Several risk factors for internal organ involvement were identified: presence of myalgia/arthralgia (odds ratio [OR] = 3.05, confidence interval [CI] 1.29−7.22), fatigue (OR = 2.53, CI 1.11−5.73) and age older than 50 years (OR = 2.23, CI 1.01−4.93).Internal organ involvement is frequent in SS, however there is no significant difference between pSS and sSS concerning its occurrence.","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":" August","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141823780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Both bullous pemphigoid and mucous membrane pemphigoid are autoimmune bullous diseases that can be challenging to treat in individual cases. Janus kinase inhibitors have shown efficacy in several autoimmune and inflammatory diseases, although these drugs are not yet widely used in autoimmune bullous diseases. We report two recalcitrant cases of pemphigoid with mucous membrane involvement which were successfully treated with the JAK 1/2 inhibitor baricitinib after all other feasible therapeutic options had been exhausted.
{"title":"Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib","authors":"Tamás Malkovics, Orsolya N. Horváth, Miklós Sárdy","doi":"10.1002/jvc2.511","DOIUrl":"https://doi.org/10.1002/jvc2.511","url":null,"abstract":"Both bullous pemphigoid and mucous membrane pemphigoid are autoimmune bullous diseases that can be challenging to treat in individual cases. Janus kinase inhibitors have shown efficacy in several autoimmune and inflammatory diseases, although these drugs are not yet widely used in autoimmune bullous diseases. We report two recalcitrant cases of pemphigoid with mucous membrane involvement which were successfully treated with the JAK 1/2 inhibitor baricitinib after all other feasible therapeutic options had been exhausted.","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":" February","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141823934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis associated with certain neoplasms, predominantly of haematological origin, and autoimmune diseases. Pemphigus vulgaris (PV) is a disease in which antibodies target crucial intercellular junction components. A few cases of PG associated with PV have been described. We present a woman with a high phototype presenting this rare association and highlight the diagnostic challenge of diagnosing rare diseases in patients with high phenotypes.
{"title":"Association between pemphigus vulgaris and pyoderma gangrenosum","authors":"Ana M. Cano, Valentina Burbano, Ricardo A. Rueda","doi":"10.1002/jvc2.507","DOIUrl":"10.1002/jvc2.507","url":null,"abstract":"<p>Pyoderma gangrenosum (PG) is a neutrophilic dermatosis associated with certain neoplasms, predominantly of haematological origin, and autoimmune diseases. Pemphigus vulgaris (PV) is a disease in which antibodies target crucial intercellular junction components. A few cases of PG associated with PV have been described. We present a woman with a high phototype presenting this rare association and highlight the diagnostic challenge of diagnosing rare diseases in patients with high phenotypes.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"3 3","pages":"902-905"},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.507","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141667259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}